Dr. Anthony Bahinski is Chief Technology Officer at Vivodyne, where he leads the translation of Vivodyne鈥檚 automated platform for massively scalable safety and efficacy testing on lifelike lab-grown human tissues to pharmaceutical and regulatory partners. Prior to joining Vivodyne, he served as the Global Head of Safety Pharmacology at GlaxoSmithKline. At GlaxoSmithKline, his responsibilities were focused on coordinating a global strategy to investigate safety risks of drugs on the cardiovascular, respiratory, CNS, renal, and other specialized tissues, both in vitro and in vivo. Dr. Bahinski鈥檚 career spans academic research and large Pharma, with more than 20 years鈥� experience in the pharmaceutical industry. He served as Lead Senior Staff Scientist on the Advanced Technology Team at Harvard鈥檚 Wyss Institute, leading DARPA and FDA collaborative efforts in development of organ chip systems. Dr. Bahinski has served on several advisory boards and is a currently member of the Science Board of the US FDA, the Industrial Advisory Board for Dutch Research Council awarded SMART Organ on Chip (OoC) project, and formerly of the US EPA Board of Scientific Counselors (BOSC). He is a member of the Editorial Board of the journals, Applied In Vitro Toxicology and Frontiers in Pharmacology of Ion Channels and Channelopathies. He has served on Peer Review Panels at the NIH, US EPA and NCI SBIR. Dr. Bahinski is author/co-author of over 40 publications including peer-reviewed articles and book chapters.